CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical...
Clinical Trial
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for...
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for...
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4...
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4...
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M...
Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs)
Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2...
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M...
Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs)
Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2...
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority...
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority...
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma...
Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients
Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in...
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"),...
Trumps Marijuana Reclassification is Only the Beginning: Why MMJ International Holdings Takes the Lead in the Medicare and Research Reset
"Federal Marijuana Reform Is Coming-But FDA-Ready Companies Will Benefit the most" Duane Boise CEO MMJ International Holdings stated. WASHINGTON, DC...
CISCRP Unveils First-Ever Interactive Data Dashboard for Global Clinical Research Insights
BOSTON, Dec. 17, 2025 /PRNewswire/ -- The Center for Information and Study on Clinical Research Participation (CISCRP) has launched an...
Enhancing Signal Detection and Mitigating Placebo Response in Major Depressive Disorder Clinical Trials, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn practical signal detection approaches that reduce placebo response and improve clinician-rated outcomes in major depressive...
Xtalks Releases 2025 Webinar Year-in-Review Showcasing Key Life Science Trends
TORONTO, Dec. 17, 2025 /PRNewswire/ -- Xtalks — The Life Science Community™, a leading B2B digital media platform serving the...
Bioptimus Unveils M-Optimus, a World Model for Biology
Revolutionary model represents a transformative step toward AI-powered virtual tissues, patient digital twins, and a new era of data-driven biomedical...
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell
RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing...